Mertiva AB

Equities

MERT A

SE0010023432

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets
- ^SEK	-

2017	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
2017	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI

Diamyd Medical AB Announces Group Earnings Results for the First Quarter Ended November 30, 2012

January 23, 2013 at 04:02 am EST

Diamyd Medical AB announced group earnings results for the first quarter ended November 30, 2012. For the quarter, the company's loss before tax amounted to SEK 1.8 million against SEK 3.5 million a year ago. Loss per share after dilution was SEK 0.2 against 0.3 a year ago.

Latest news about Mertiva AB

Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	17-08-27	CI
Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	17-08-10	CI
Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million	17-07-10	CI
Mertiva AB's Equity Buyback announced on December 6, 2012, has expired.	15-11-28	CI
Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million.	14-12-17	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	14-01-21	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	13-10-11	CI
The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B).	13-10-08	CI
Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million.	13-09-25	CI
Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index	13-08-27	CI
Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index	13-07-30	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	13-07-04	CI
Diamyd Medical AB Announces Board Appointments	13-04-22	CI
Diamyd Medical AB Names Andreas Bergsten as Chief Executive Officer	13-04-22	CI
Diamyd Medical AB has Changed its Name to Mertiva AB	13-04-22	CI
Mertiva AB Plans to Appoint Andreas Bergsten as President	13-04-19	CI
Diamyd Medical AB Reports Group Earnings Results for the Second Quarter and Six Months Ended February 28, 2013	13-03-27	CI
Tranche Update on Diamyd Medical AB's Equity Buyback Plan announced on December 6, 2012.	13-03-27	CI
Östersjöstiftelsen, Endowment Arm sold 5.1% stake in Diamyd Medical AB (OM:DIAM B).	13-03-06	CI
Diamyd Medical AB Announces New Clinical Study with Diamyd's Diabetes Vaccine	13-01-30	CI
Diamyd Medical AB Announces Group Earnings Results for the First Quarter Ended November 30, 2012	13-01-23	CI
Diamyd Medical AB Announces Board Changes	12-12-06	CI
Diamyd Medical AB's Equity Buyback has expired	12-12-06	CI
Mertiva AB announces an Equity Buyback.	12-12-05	CI
Tranche Update on Diamyd Medical AB's Equity Buyback Plan announced on December 7, 2011.	12-12-05	CI

Chart Mertiva AB

Duration

Period

More charts

Company Profile

Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MERTIVA AB	0.00%	89.46M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research